Table 5 Sensitivity analyses of use of 5α-reductase inhibitors and risk of oesophageal and gastric cancer by histological type and anatomical sub-site.
Outcomes | Number of cases in users/non-users | Adjusted hazard ratio (95% confidence interval)* |
|---|---|---|
Excluding participants with <1 year of follow-up | ||
Oesophageal or gastric cardia adenocarcinoma | ||
Non-user | 2385 | 1.00 (Reference) |
User | 247 | 0.94 (0.82–1.07) |
Gastric non-cardia adenocarcinoma | ||
Non-user | 1707 | 1.00 (Reference) |
User | 182 | 0.96 (0.82–1.12) |
Oesophageal squamous cell carcinoma | ||
Non-user | 684 | 1.00 (Reference) |
User | 40 | 0.55 (0.40–0.76) |
Censoring those diagnosed with other cancers during follow-up | ||
Oesophageal or gastric cardia adenocarcinoma | ||
Non-user | 3328 | 1.00 (Reference) |
User | 345 | 0.94 (0.84–1.05) |
Gastric non-cardia adenocarcinoma | ||
Non-user | 2567 | 1.00 (Reference) |
User | 264 | 0.92 (0.81–1.05) |
Oesophageal squamous cell carcinoma | ||
Non-user | 985 | 1.00 (Reference) |
User | 53 | 0.50 (0.38–0.67) |
